{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:38:23Z","timestamp":1778629103357,"version":"3.51.4"},"reference-count":22,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2007,3,2]],"date-time":"2007-03-02T00:00:00Z","timestamp":1172793600000},"content-version":"vor","delay-in-days":6575,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[1989,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ten patients with refractory B cell lymphomas were treated with weekly intravenous infusions of escalating doses of murine monoclonal antibody (MoAb) LYM\u20101 over four weeks. LYM\u20101 is a recently developed IgG2a murine MoAb that recognizes a polymorphic HLA\u2010Dr antigen on surfaces of normal and malignant B cells but does not bind to any other normal tissues. MoAb LYM\u20101 has several advantages for serotherapy, since the antigen it recognizes is not shed from the cell surface and does not modulate in response to MoAb therapy. Furthermore, <jats:italic>in vitro<\/jats:italic> studies have indicated significant anti\u2010tumour activity against lymphoma cell lines. In the current trial, dose\u2010dependent levels of free LYM\u20101 were detected in the serum of all patients, but penetration of extravascular tumour tissues was poor. No significant toxicity or human anti\u2010mouse antibody responses were observed in any patient. Clinical responses were minor and appeared to correlate with the number of infiltrating T cells seen in the initial lymphoma specimens. LYM\u20101 appears to be well\u2010tolerated and has demonstrated several potential advantages as a therapeutic agent in patients with lymphoma. The mechanism of anti\u2010tumour effect and plans for further clinical studies are discussed.<\/jats:p>","DOI":"10.1002\/hon.2900070207","type":"journal-article","created":{"date-parts":[[2007,2,19]],"date-time":"2007-02-19T20:07:41Z","timestamp":1171915661000},"page":"155-166","source":"Crossref","is-referenced-by-count":59,"title":["A phase 1a clinical trial of LYM\u20101 monoclonal antibody serotherapy in patients with refractory b cell malignancies"],"prefix":"10.1002","volume":"7","author":[{"given":"Eddie","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan L.","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory S.","family":"Naeve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Indraini","family":"Gill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sue","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andy","family":"Sherrod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amitabha","family":"Mazumder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra M.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,3,2]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"crossref","unstructured":"Denardo S. J. Denardo G. L. O'Grady L. F.(1987).Treatment of a patient with B cell lymphoma by [131I] LYM\u20101 monoclonal antibodies.Int. J. Biol. Markers in press.","DOI":"10.1177\/172460088700200107"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(84)80008-6"},{"key":"e_1_2_1_4_1","first-page":"230","article-title":"Toxicity and efficacy of 24 hour infusions of T101 monoclonal antibodies in chronic lymphocytic leukemia and cutaneous T cell lymphoma","volume":"4","author":"Dillman R. O.","year":"1985","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4613-2607-6_60"},{"key":"e_1_2_1_6_1","first-page":"830","article-title":"Two new monoclonal antibodies, LYM\u20101 and LYM\u20102, reactive with human B lymphocytes and derived tumours, with immunodiagnostic and immunotherapeutic potential","volume":"47","author":"Epstein A. L.","year":"1987","journal-title":"Cancer Res."},{"key":"e_1_2_1_7_1","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1182\/blood.V64.5.1085.1085","article-title":"Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia","volume":"64","author":"Foon K. A.","year":"1984","journal-title":"Blood"},{"key":"e_1_2_1_8_1","doi-asserted-by":"crossref","first-page":"653","DOI":"10.4049\/jimmunol.135.1.653","article-title":"The generation of monoclonal antibodies to human B cell derived leukemias and lymphomas","volume":"135","author":"Giardina S. L.","year":"1985","journal-title":"J. Immunol."},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1985.3.3.340"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1089\/hyb.1.1982.1.423"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0147-0272(86)80012-5"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V65.6.1349.bloodjournal6561349"},{"key":"e_1_2_1_13_1","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1182\/blood.V62.5.988.988","article-title":"Monoclonal antibody therapeutic trials in seven patients with T\u2010cell lymphoma","volume":"62","author":"Miller R. A.","year":"1983","journal-title":"Blood"},{"key":"e_1_2_1_14_1","first-page":"3147","article-title":"Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma associated antigen","volume":"40","author":"Nadler L. M.","year":"1980","journal-title":"Cancer Res."},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1983.1.9.582"},{"key":"e_1_2_1_16_1","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1182\/blood.V69.2.584.584","article-title":"Monoclonal antibody IF5 serotherapy of human B cell lymphomas","volume":"69","author":"Press O. W.","year":"1987","journal-title":"Blood"},{"key":"e_1_2_1_17_1","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1182\/blood.V65.6.1373.bloodjournal6561373","article-title":"Treatment of two patients with B cell lymphoma with monoclonal anti\u2010idiotype antibodies","volume":"65","author":"Rankin E. M.","year":"1985","journal-title":"Blood"},{"key":"e_1_2_1_18_1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood.V58.1.141.141","article-title":"Serotherapy of acute lymphoblastic leukemia with monoclonal antibody","volume":"58","author":"Ritz J.","year":"1981","journal-title":"Blood"},{"key":"e_1_2_1_19_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V59.1.1.1","article-title":"Utilization of monoclonal antibodies in the treatment of leukemia and lymphoma","volume":"59","author":"Ritz J.","year":"1982","journal-title":"Blood"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198512053132327"},{"key":"e_1_2_1_21_1","first-page":"503","article-title":"Specific targeting of chlorambucil to tumours with the use of monoclonal antibodies","volume":"76","author":"Smythe M. J.","year":"1986","journal-title":"JNCI"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/29.10.7028859"},{"key":"e_1_2_1_23_1","doi-asserted-by":"crossref","first-page":"238","DOI":"10.4049\/jimmunol.125.1.238","article-title":"The isolation and growth of lymphoid cells infiltrating solid tumours","volume":"125","author":"Yron I.","year":"1980","journal-title":"J. Immunol."}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2900070207","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2900070207","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T11:17:46Z","timestamp":1697973466000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2900070207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1989,3]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1989,3]]}},"alternative-id":["10.1002\/hon.2900070207"],"URL":"https:\/\/doi.org\/10.1002\/hon.2900070207","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[1989,3]]}}}